05.12.23
Thermo Fisher Scientific has introduced a new line of ion exchange columns for biopharmaceutical research labs designed to deliver superior reproducibility, sensitivity and durability for charge-based analysis of therapeutic proteins and separation of full vs. empty adeno-associated virus (AAV) capsids used for gene therapy.
The Thermo Scientific ProPac 3R HPLC column portfolio leverages a novel monodisperse particle platform and state-of-the-art separation power to deliver lot-to-lot reproducibility and consistent results over the lifecycle of a drug, from research and development to commercialization. According to the company, the new 3 μm particle size enables a new level of performance with ultra-high resolution of charge variants, improved peak resolution and faster run times.
The portfolio supports strong anion-exchange (SAX) and strong cation-exchange (SCX) column chemistries, each with two column lengths (50mm and 100mm) and two inner diameters (2mm and 4mm).
The ProPac 3R HPLC column portfolio is designed for biopharmaceutical labs performing charge variant analysis of therapeutic proteins, including monoclonal antibodies, and separation of full versus empty AAV capsids used for gene therapy.
Features include:
• Compatible with the mobile phases and organic solvents used in biopharmaceutical applications
• Designed with bio-inert materials to reduce secondary interactions
• Improved peak-to-valley resolution of charge variants to increase certainty of quantification of critical quality attributes
• Detection and identification of new acidic or basic variants during late-stage development
• High sample-loading capacity
• Analytical flexibility for excellent sensitivity and performance under a broad range of pH, temperature, and mobile phase compositions as well as MS capabilities
The Thermo Scientific ProPac 3R HPLC column portfolio leverages a novel monodisperse particle platform and state-of-the-art separation power to deliver lot-to-lot reproducibility and consistent results over the lifecycle of a drug, from research and development to commercialization. According to the company, the new 3 μm particle size enables a new level of performance with ultra-high resolution of charge variants, improved peak resolution and faster run times.
The portfolio supports strong anion-exchange (SAX) and strong cation-exchange (SCX) column chemistries, each with two column lengths (50mm and 100mm) and two inner diameters (2mm and 4mm).
The ProPac 3R HPLC column portfolio is designed for biopharmaceutical labs performing charge variant analysis of therapeutic proteins, including monoclonal antibodies, and separation of full versus empty AAV capsids used for gene therapy.
Features include:
• Compatible with the mobile phases and organic solvents used in biopharmaceutical applications
• Designed with bio-inert materials to reduce secondary interactions
• Improved peak-to-valley resolution of charge variants to increase certainty of quantification of critical quality attributes
• Detection and identification of new acidic or basic variants during late-stage development
• High sample-loading capacity
• Analytical flexibility for excellent sensitivity and performance under a broad range of pH, temperature, and mobile phase compositions as well as MS capabilities